Claims
- 1. A method for treating cancer in a patient having cancer, comprising administering a composition comprising Flt3-ligand.
- 2. The method of claim 1, wherein the Flt3-ligand stimulates the proliferation of hematopoietic stem or progenitor cells.
- 3. The method of claim 1, wherein the Flt3-ligand stimulates the proliferation of cells selected from the group consisting of myeloid precursor cells, monocytic cells, macrophages, B-cells and dendritic cells.
- 4. A method of increasing the number of dendritic cells in a patient having cancer, comprising administering a composition comprising Flt3-ligand.
- 5. A method of augmenting tumor-specific immune responses in a patient having cancer, comprising administering a composition comprising Flt3-ligand.
- 6. A method of reducing tumor growth in a patient having cancer, comprising administering a composition comprising Flt3-ligand.
- 7. A method of reducing tumor incidence in a patient having cancer, comprising administering a composition comprising Flt3-ligand.
- 8. A method of increasing tumor rejection in a patient having cancer, comprising administering a composition comprising Flt3-ligand.
- 9. The method of claim 1, wherein the Flt3-ligand is human Flt3-ligand.
- 10. The method of claim 1, wherein the Flt3-ligand is soluble human Flt3-ligand.
- 11. The method of claim 1, wherein the Flt3-ligand comprises an amino acid sequence that is at least 80% identical to amino acids 28 to Xaa of SEQ ID NO:2, wherein Xaa is an amino acid from 160 to 235.
- 12. The method of claim 1, wherein the Flt3-ligand comprises amino acids 28 to Xaa of SEQ ID NO:2, wherein Xaa is an amino acid from 160 to 235.
- 13. The method of claim 1, wherein the Flt3-ligand comprises amino acid residues 28-160 of SEQ ID NO:2.
- 14. The method of claim 1, wherein the Flt3-ligand comprises amino acid residues 28-182 of SEQ ID NO:2.
- 15. The method of claim 1, wherein the Flt3-ligand further comprises a pharmaceutically suitable carrier, diluent and/or preservative.
- 16. The method of claim 1, wherein the Flt3-ligand is complexed with polyethylene glycol.
- 17. The method of claim 1, wherein the Flt3-ligand is administered topically, parenterally or by inhalation.
RELATED APPLICATIONS
[0001] This application is a continuation of U.S. application Ser. No. 09/444,027, filed Nov. 19, 1999, now abandoned, which is a continuation-in-part of U.S. application Ser. No. 09/154,903, filed Sep. 17, 1998, now abandoned, which is a continuation-in-part of U.S. application Ser. No. 08/725,540, filed Oct. 3, 1996, now abandoned, which is continuation-in-part of U.S. application Ser. No. 08/539,142, filed Oct. 4, 1995, now abandoned.
Continuations (1)
|
Number |
Date |
Country |
Parent |
09444027 |
Nov 1999 |
US |
Child |
10241927 |
Sep 2002 |
US |
Continuation in Parts (3)
|
Number |
Date |
Country |
Parent |
09154903 |
Sep 1998 |
US |
Child |
09444027 |
Nov 1999 |
US |
Parent |
08725540 |
Oct 1996 |
US |
Child |
09154903 |
Sep 1998 |
US |
Parent |
08539142 |
Oct 1995 |
US |
Child |
08725540 |
Oct 1996 |
US |